Innovation Platform: Collaboration
Ferring PharmaceuticalsFerring Pharmaceuticals has since 2015 been the main industry partner in ReproUnion and provided critical expertise in reproductive medicine. From its R&D headquarters in Copenhagen, the Ferring project representatives have played an important role in advancing the translational research potential of ReproUnion activities.
This collaboration continues to enable the validation of new findings within clinical and regulatory contexts and it strengthens the link between academic innovation and real-world applications. In a recent podcast from Business Review Life Science, you can meet Kelle Moley, Vice President, Reproductive Medicine and Maternal Health at Ferring, alongside Professor Eva Hoffmann, University of Copenhagen and CEO Anette Steenberg, Medicon Valley Alliance.
They discuss the role of platforms like ReproUnion with a focus on understanding the underlying causes of infertility, as well as the role of the public-private partnerships in addressing the challenge of falling fertility rates. They first explore the societal impact of involuntary childlessness and the broader implications this can have on the world.